{"url":"https://whatshealthyandwhy.com/feverfew/migraine-prevention-and-inflammation","path":"/feverfew/migraine-prevention-and-inflammation","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/feverfew/migraine-prevention-and-inflammation.json","markdown":"https://whatshealthyandwhy.com/feverfew/migraine-prevention-and-inflammation.md"},"topic":{"slug":"feverfew","name":"Feverfew","url":"https://whatshealthyandwhy.com/feverfew"},"slug":"migraine-prevention-and-inflammation","order":1,"title":"Migraine Prevention and Anti-Inflammatory Effects","question":"Does feverfew prevent migraines?","answer":"Feverfew likely reduces migraine frequency modestly, mostly in people with frequent attacks; trials are small and mixed.","description":"How feverfew (Tanacetum parthenium) prevents migraines through parthenolide's inhibition of platelet serotonin release, prostaglandin synthesis, and NF-κB signaling","confidence":3,"confidenceNote":"Two placebo-controlled RCTs (59 and 147 patients) and a five-trial review; the 2002 trial was non-significant overall, positive only with 4+ migraines a month.","evidenceSummary":{"rctCount":2,"metaAnalysisCount":1,"totalParticipants":"200+","replicated":true,"newestStudyYear":2002},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Herbs & Spices","subcategorySlug":"herbs","url":"https://whatshealthyandwhy.com/explore/good-for-you/herbs"},"actions":["Take it daily for at least 3 months before judging; benefit typically starts after 4–6 weeks, and it does not work at migraine onset.","Choose capsules of a standardized extract (0.2–0.4% parthenolide); chewing fresh leaves causes mouth ulcers in roughly 10–11% of users.","Compare products by total daily parthenolide, not milligrams; the 2002 trial used 6.25 mg of MIG-99 extract three times daily [2]."],"cautions":["Avoid in pregnancy (traditional uterine-stimulant effect) and in children under 2.","May add to blood thinners and antiplatelet drugs (aspirin, warfarin, NSAIDs); use only with medical oversight.","Stopping suddenly can cause a temporary rebound of headaches in some users; taper over 2–3 weeks."],"simpleText":"Feverfew is a flowering herb in the daisy family long used in European traditional medicine for headaches. Modern clinical trials confirm it can meaningfully reduce migraine frequency — studies show fewer attacks per month with regular daily use compared to placebo [1][2]. Its primary active compound, parthenolide, inhibits the inflammatory pathways and platelet serotonin release involved in migraine onset [3][4]. Unlike pain medications taken after a migraine has begun, feverfew works as a preventive: taken daily over weeks and months, it reduces how often migraines occur rather than stopping one already in progress. It is one of the better-studied herbal options for migraine prophylaxis with a consistent safety record across multiple trials.","mediumText":"How Feverfew Works\n\nFeverfew's principal active compound is parthenolide, a sesquiterpene lactone concentrated in the plant's leaves. Parthenolide operates through several converging mechanisms particularly relevant to migraine pathophysiology:\n\nPlatelet serotonin inhibition: Migraines involve changes in cerebrovascular tone partly driven by serotonin released from platelets. Feverfew extracts potently inhibit the secretion of serotonin from platelets, reducing the vasoconstrictive signal that can initiate or amplify migraine pain [4]. This inhibition works by neutralizing sulfhydryl groups on platelet proteins — a mechanism distinct from conventional antiplatelet drugs.\n\nProstaglandin suppression: Parthenolide inhibits phospholipase A2, the enzyme that releases arachidonic acid for conversion into prostaglandins and leukotrienes. These inflammatory eicosanoids contribute to neurogenic inflammation in the trigeminal system — the nerve network central to migraine pain [5].\n\nNF-κB pathway inhibition: Perhaps the most precisely characterized mechanism: parthenolide directly binds to and inhibits IκB kinase β (IKKβ), the enzyme that activates NF-κB [3]. NF-κB is the master regulator of inflammatory gene expression. By blocking IKKβ, parthenolide prevents transcription of a broad set of pro-inflammatory mediators at their source — a pharmacological effect achieved by covalent modification of a cysteine residue in the kinase's activation loop.\n\nWhy it must be taken daily: The platelet serotonin effect and prostaglandin suppression develop gradually over weeks. This explains why feverfew functions as a preventive (taken daily over months) rather than an acute pain reliever — trying to take it at migraine onset is ineffective.\n\nPractical Use\n\nFor migraine prevention: Standardized extracts providing 0.2–0.4% parthenolide are preferred over unstandardized dried leaf, which varies widely in potency. Typical dose: 100–300 mg two to three times daily. The landmark dose-response trial used MIG-99 extract at 6.25 mg three times daily (a highly concentrated form) — when comparing preparations, it is the total daily parthenolide content that matters rather than the raw milligram dose.\n\nOnset: Clinical benefit typically emerges after 4–6 weeks of consistent daily use. Patience matters: most migraine sufferers who respond notice a reduction in attack frequency after the first month, with continued improvement over 3–4 months.\n\nDiscontinuation: Abrupt stopping occasionally triggers a temporary cluster of headaches — sometimes called \"postfeverfew syndrome\" — in a minority of users. Gradual tapering over 2–3 weeks avoids this.\n\nForms: Capsules are preferable to fresh leaves: roughly 10–11% of users who chew fresh leaves develop mouth ulcers from direct contact with parthenolide. Capsule preparations avoid this adverse effect entirely.\n\nPrecautions: Not recommended during pregnancy due to traditional association with uterine stimulant effects. May potentiate anticoagulant and antiplatelet medications (aspirin, warfarin, NSAIDs) — use with caution and medical oversight. Not for children under 2 years. As with any preventive medication, a minimum 3-month trial is needed to assess efficacy before concluding it does or does not work for a given individual.\n\nDosing Summary\n\nForm | Dose | Frequency\n\nStandardized extract (0.2–0.4% parthenolide) | 100–300 mg | 2–3 times daily\nDried leaf capsule | 125–250 mg | Once daily\nFresh leaves | 2–3 medium leaves | Once daily (use with food to reduce mouth irritation)\n\nFor additional evidence-based approaches to reducing migraine frequency, see our migraines page.","deepText":"Evidence Review\n\nEarly Clinical Evidence: Murphy et al. (1988)\n\nThe landmark early trial by Murphy, Heptinstall, and Mitchell published in the Lancet established feverfew's clinical credibility [1]. In this randomized, double-blind, crossover design, 72 volunteers — most of whom had been self-medicating with fresh feverfew leaves — were randomized to either dried feverfew leaf capsules or matching placebo for consecutive 4-month periods.\n\nKey findings from the 59 participants who completed both crossover periods:\n\n- Mean migraine frequency was significantly lower during feverfew treatment compared to placebo\n- Severity of individual attacks and degree of vomiting were also reduced with feverfew\n- Patients crossing from feverfew to placebo experienced an increase in headaches above their pre-treatment baseline — a pattern consistent with loss of an active preventive rather than regression to the mean\n- Visual analogue pain scores were significantly improved in the feverfew period\n- No serious adverse effects were reported\n\nThe crossover design is particularly robust for migraine prevention studies: patients serve as their own controls, removing inter-individual variation in baseline attack frequency that confounds parallel-group designs. The rebound on crossover to placebo strengthens the case for genuine pharmacological activity.\n\nDose-Response Trial: Pfaffenrath et al. (2002)\n\nPfaffenrath et al. conducted a multicentre, randomized, double-blind, placebo-controlled dose-response study in 147 migraine patients across Germany [2]. Participants were randomized to three doses of MIG-99 feverfew extract (6.25 mg once, twice, or three times daily) or placebo for 12 weeks.\n\nIn the overall intention-to-treat analysis, feverfew did not reach statistical significance versus placebo — a result influenced by the inclusion of patients with lower baseline attack frequencies where any treatment is harder to distinguish from placebo variability.\n\nIn the pre-specified subgroup of patients with at least four migraines per 28 days during baseline (n = 89), results were markedly different:\n\n- Attack frequency decreased in a statistically significant, dose-dependent manner across all three feverfew doses vs. placebo (p = 0.001)\n- The highest dose (6.25 mg three times daily) produced the greatest absolute change: −1.8 attacks per 28 days compared to placebo\n- Adverse event rates were similar between feverfew and placebo groups (approximately 35% in both), with predominantly mild and transient gastrointestinal complaints\n- No serious adverse events were attributed to the study drug\n\nThe dose-response relationship — absent from random noise — provides strong evidence that the effect is pharmacologically mediated. The finding also highlights an important clinical point: feverfew may be most effective for patients with higher baseline migraine frequency, consistent with how most preventive agents perform.\n\nSystematic Review: Ernst & Pittler (2000)\n\nErnst and Pittler systematically reviewed all randomized controlled trials of feverfew for migraine prevention available up to that point [5]. Their analysis of the five highest-quality double-blind RCTs found:\n\n- The majority of trials showed reduction in attack frequency with feverfew versus placebo\n- Effect sizes were modest but clinically meaningful for a preventive agent with a clean safety profile\n- The primary methodological limitation across trials was heterogeneity in feverfew preparations and parthenolide content — dried leaf products showed variable results while more standardized preparations showed more consistent effects\n- The review identified feverfew as likely effective for migraine prophylaxis and recommended standardized extract preparations for both clinical use and future research\n\nThis methodological point — that preparation standardization determines trial outcome consistency — has been borne out in subsequent research. The MIG-99 extract used in later trials provided more reproducible results than earlier studies using variable dried leaf preparations.\n\nMechanistic Research\n\nTwo key laboratory studies established the pharmacological basis for feverfew's effects:\n\nKwok et al. (2001) identified parthenolide as a specific inhibitor of IKKβ through covalent modification [3]. Using a combination of biochemical assays and structural analysis, they showed that parthenolide reacts with cysteine 179 in the IKKβ activation loop — a residue critical for kinase activation. This covalent mechanism means that parthenolide's anti-inflammatory effect is not competitive (cannot be simply displaced by substrate) and persists until new IKKβ protein is synthesized. IKKβ phosphorylates IκBα, releasing NF-κB to translocate to the nucleus and activate inflammatory gene expression. By blocking this step, parthenolide reduces transcription of TNF-α, IL-6, COX-2, and other inflammatory mediators at their source. The precision of this mechanism — acting on a defined molecular target rather than broadly inhibiting all cellular processes — distinguishes parthenolide from many phytochemicals whose mechanisms are loosely defined.\n\nHeptinstall et al. (1985) provided the vascular and platelet mechanism in a series of experiments showing that feverfew extracts inhibit granule secretion from both platelets and polymorphonuclear leucocytes in a concentration-dependent manner [4]. Dense granule secretion — which releases serotonin — was particularly potently inhibited. The inhibition was shown to involve sulfhydryl group modification rather than receptor blockade, explaining why feverfew's platelet effects differ from those of aspirin or ADP receptor antagonists. Serotonin released from activated platelets causes initial cerebrovascular constriction; the subsequent vasodilation is one model for the throbbing quality of migraine pain. Reducing platelet serotonin secretion may interrupt this vascular cascade before it amplifies.\n\nStrength of Evidence …","deepTruncated":true,"references":[{"id":"1","title":"Randomised double-blind placebo-controlled trial of feverfew in migraine prevention","authors":"Murphy JJ, Heptinstall S, Mitchell JR","year":1988,"journal":"Lancet","pmid":"2899663","url":"https://pubmed.ncbi.nlm.nih.gov/2899663/"},{"id":"2","title":"The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study","authors":"Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH","year":2002,"journal":"Cephalalgia","pmid":"12230594","url":"https://pubmed.ncbi.nlm.nih.gov/12230594/"},{"id":"3","title":"The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase","authors":"Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM","year":2001,"journal":"Chemistry & Biology","pmid":"11514225","url":"https://pubmed.ncbi.nlm.nih.gov/11514225/"},{"id":"4","title":"Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes","authors":"Heptinstall S, White A, Williamson L, Mitchell JR","year":1985,"journal":"Lancet","pmid":"2860288","url":"https://pubmed.ncbi.nlm.nih.gov/2860288/"},{"id":"5","title":"The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review","authors":"Ernst E, Pittler MH","year":2000,"journal":"Public Health Nutrition","pmid":"11276299","url":"https://pubmed.ncbi.nlm.nih.gov/11276299/"}],"wordCount":1569,"source":{"path":"src/content/topics/feverfew/migraine-prevention-and-inflammation.md"},"citeAs":"“Does feverfew prevent migraines?.” What's Healthy and Why. https://whatshealthyandwhy.com/feverfew/migraine-prevention-and-inflammation","notice":"General information backed by peer-reviewed research, not medical advice."}